Comparison · NCT00844649-sae
Albumin-bound Paclitaxel (ABI-007)/Gemcitabine vs Gemcitabine: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Albumin-bound Paclitaxel (ABI-007)/Gemcitabine vs Gemcitabine: serious adverse events. Trial comparisons, record NCT00844649-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00844649-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.504 | 0.456 | 0.551 | wilson | |
| Risk in group 2 | 0.428 | 0.38 | 0.477 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0757 | 0.00753 | 0.143 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.18 | 1.02 | 1.36 | log | |
| Odds ratio, group 1 over group 2 | 1.36 | 1.03 | 1.79 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Albumin-bound Paclitaxel (ABI-007)/Gemcitabine than on Gemcitabine | 13.2 | 7 | 133 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Albumin-bound Paclitaxel (ABI-007)/Gemcitabine | Albumin-bound paclitaxel (ABI-007)/Gemcitabine: ABI-007 125 mg/m\^2 administered intravenously (IV) in combination with Gemcitabine 1000 mg/m\^2 IV weekly for 3 weeks on Days 1, 8, and 15 followed by one week of rest | 212 | 421 | EG000 |
| Group 2 | Gemcitabine | Gemcitabine 1000 mg/m\^2 administered IV weekly for 7 weeks through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks on Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward) | 172 | 402 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Day 1 up to 30 days after the last dose (a maximum of 666 days)
Source ClinicalTrials.gov
Trial
- Title
- Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
- NCT number
- NCT00844649
- Phases
- PHASE3
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Albumin-bound paclitaxel (ABI-007), Gemcitabine
- Lead sponsor
- Celgene
- Results first posted
- 2013-12-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00844649?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00844649-sae